BackgroundIn this case study Emma Cains describes a series of experiments that ultimately resulted in a 10-fold increase in expression with a ‘difficult to express protein’. The initial work involved comparing expression in HEK293-6E and CHO-3E7 cells, followed by the use of a high cell [...]
The key to delivering a FBDD project was optimising the crystal system
Richard Mott2024-12-02T11:45:15+00:00In this case study, Ariadna Juarez-Martinez describes how optimising the crystal system for a target protein was ultimately the key to delivering a successful fragment screen for one of our clients. 152 high-confidence fragments were identified that bound across 24 binding hotspots on the [...]
Determining the Cryo-EM Structure of the 5-HT2A receptor with Serotonin Bound
Richard Mott2025-01-22T10:03:01+00:00In this case study, Rachel Johnson describes how we determined the active state structure of the 5-HT2A receptor with the natural ligand serotonin bound using cryo-EM. Introduction GPCRs are a large and diverse group of receptors in the body. They are also important therapeutic targets [...]
Fragment Screening by Crystallography: An Alternative to High Throughput Screening
Richard Mott2025-01-22T10:02:26+00:00In this Case Study Helen Gingell and Thirumalai Ulaganathan give an introduction to Fragment based drug discovery (FBDD) with a focus on using X-ray crystallography to perform FBDD. This is exemplified with a description of a project in which Sygnature Discovery ran a fragment [...]
Production of Active VHL and Analysis by SPR
Peak Proteins2025-10-13T10:49:26+00:00Proximity Based Therapeutics Proximity based therapeutics have emerged as powerful tools in drug discovery and come in a wide range of different formats, including molecular glues and PROTACs (Proteolysis Targeting Chimeras). In all cases a molecule is used to bring together two cellular proteins: [...]
Development of a Refolding Protocol for an Interleukin
Richard Mott2024-04-30T07:37:25+00:00One of our Senior Protein Scientists, Sam Bloor, describes the journey to develop a refolding route for an interleukin. Introduction Cytokines are important cell signalling proteins which bind to cell surface receptors, initiating downstream cascades 1. They have a range of functions such as [...]
Enhancing Biotherapeutic Protein yield through CHO Expression Optimisation
Richard Mott2024-04-22T14:31:44+00:00In this case study, Emma Cains and Anna Bennett conducted a series of optimisation experiments that led to a ten-fold yield increase of a Biotherapeutic protein. Background Peak Proteins offers CHO, (CHO-3E7) HEK293-6E and HEK Expi293 expression systems for transient mammalian protein production. The [...]
Using the BacMam System in HEK293-6E cells to Generate High Level Expression of a Membrane Protein
Richard Mott2024-02-29T10:05:54+00:00In this case study Sarah Beck outlines our recent success using the BacMam system in HEK293-6E cells to generate high level expression of a GFP-tagged membrane protein required by a client on a large-scale. Introduction At Peak Proteins, as well as producing many classes [...]
The Journey To Solve a Challenging Protein Purification
Richard Mott2024-02-27T14:07:18+00:00In this case study, Toby Allen, one of our protein scientists leads us through the various steps we took to resolve a particularly tricky protein production challenge. We worked on both a full length and truncated version of a DNA binding protein and employed [...]
Using Mass Spectrometry to Rapidly Facilitate Covalent Drug Discovery
Richard Mott2024-02-27T14:07:52+00:00The Name's Bond... Covalent Bond. Covalent compounds have historically accounted for a significant number of successful drugs, but interest waned due to concerns about poor selectivity that is often identified in early assay screening. One of the key hurdles in a covalent drug campaign [...]
